STADA Arzneimittel AG has shaken hands with Bio-Thera Solutions on an exclusive commercialization and license agreement for the Chinese firm’s BAT2506 proposed biosimilar to Janssen’s Simponi (golimumab) in the EU, the UK, Switzerland and select other countries, in the latest commercial development for what has so far proven a select pool of chasers for the anti-TNF monoclonal antibody.
Under the terms of the firms’ agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2506; while the German firm will enjoy exclusive rights
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?